We believe personnalized medicine and targeted therapies are amazing therapeutic alternatives for many patients.
Our work focus on bringing chemical innovation to antibody-drug conjugates, a sub-class of targeted therapies, in order to ensure optimal characteristics and efficacies.
To date, McSAF have developped McSAF Inside® cysteins rebridging technology platforms that can be used to produce three typologies of ADCs:
- DAR 4, i.e. 4 drugs per antibody
- DAR 2, i.e. 2 drugs per antibody
- DAR 1, i.e. 1 drug per antibody